Search
Clinician Ordering Portal
Scientific evidence
Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical practice guideline
Dec 2019
This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).
Publication: Pract Radiat Oncol
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (P1990) at UEG 2019, Barcelona
Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists
Oct 2019
To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.
Publication: JDD
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment
Sep 2019
Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice.
Publication: SKIN: Journal of Cutaneous Melanoma
Level of evidence review for a gene expression profile test for cutaneous melanoma
Jul 2019
Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.
Publication: American Journal of Clinical Dermatology
Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma
Jul 2019
Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness.
Publication: SKIN: Journal of Cutaneous Melanoma
Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients
May 2019
TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.
Publication: Podium presentation (1068) at DDW 2019, San Diego